Unsurprisingly, vertical pathway inhibition using the concurrent inhibition of KRAS G12C and SHP2 has proven effective in overcoming adaptive feedback resistance across multiple tumor histologies in preclinical studies [82]. Here, KRAS is linked to neoplasm.